In cases where FDA misses a user fee review deadline, communicating a new target date for a decision—rather then leaving an NDA or BLA in limbo—would help restore credibility and predictability to the system.
Industry consultant Bruce Burlington, who worked for FDA before leaving in 1999 to head up regulatory affairs for Wyeth, discussed...